/HCA%20Healthcare%20Inc%20logo%20on%20phone-by%20rafapress%20via%20Shutterstock.jpg)
HCA Healthcare, Inc. (HCA), based in Nashville, Tennessee, is a leading operator of an extensive network of healthcare facilities throughout the United States and the United Kingdom. The company owns, manages, or operates nearly 190 hospitals and roughly 2,400 additional sites of care, including ambulatory surgery centers, freestanding emergency departments, urgent care clinics, diagnostic centers, and more. HCA Healthcare’s market capitalization stands at approximately $96.4 billion, reflecting its substantial scale in the healthcare services sector.
Companies with a market cap of $10 billion or more are typically classified as “large-cap stocks,” denoting established firms with robust financial firepower and notable market presence. HCA Healthcare stands comfortably within this tier. This status highlights HCA’s entrenched dominance in the healthcare services arena, characterized by a powerful brand, an extensive care network, and the capacity to deliver efficient and comprehensive medical services at scale.
HCA stock has reached a fresh 52-week high of $417.20 on Sept. 4. Shares of the healthcare services operator have gained 7.8% over the past three months, slightly outperforming the broader Dow Jones Industrial Average’s ($DOWI) 7.5% rise over the same time frame.
Longer term, HCA stock is up 37.1% on a year-to-date (YTD) basis, outpacing Dow Jones’ 7.2% gains. Meanwhile, the stock has delivered around 4.4% returns over the past 52 weeks, compared to DOWI’s 11.3% returns over the same time frame.
HCA spent months wrestling below its 50-day moving average as sellers dominated late 2024. But by spring 2025, buyers took charge, driving a golden crossover as the 50-day pierced above the 200-day around June. HCA’s story flipped after months of drifting, and since June, it has been cruising above the 200-day moving average, and consistently leapt past the 50-day mark since January, although with slight fluctuations.
Each pullback has been shallow, hinting at strong buyer conviction. The trend now favors the bulls, with momentum building and dips getting scooped fast. Technicals suggest this rally might still have fuel left.
HCA’s stock performance has been shaped by strong underlying fundamentals on one hand, but cautious outlooks and broader sector headwinds persist, including deflated patient volumes and regulatory upheavals.
Its top rival, Tenet Healthcare Corporation (THC), has far exceeded HCA, with 52.5% gains this year and 18.8% over the past year.
Wall Street analysts are moderately bullish on HCA’s prospects. The stock has a consensus “Moderate Buy” rating from the 26 analysts covering it, and the stock is trading above its mean price target of $401.73. But the Street-high target of $444 suggests an upside potential of 7.9%.
On the date of publication, Sristi Jayaswal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
